BENGALURU (Reuters) – Cipla, India’s third-largest drugmaker by sales, posted a bigger-than-expected rise in second-quarter profit on Friday, boosted by strength in its domestic and North American business.
The company’s consolidated net profit climbed 43.4% to 11.31 billion rupees ($135.90 million) in the quarter ended Sept. 30, beating analysts’ average estimate of 9.75 billion rupees, as per LSEG data.
($1 = 83.2210 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru)
